Avacopan + Avacopan Matching Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
C3 Glomerulopathy (C3G)
Conditions
C3 Glomerulopathy (C3G)
Trial Timeline
Sep 29, 2017 → Oct 27, 2021
NCT ID
NCT03301467About Avacopan + Avacopan Matching Placebo
Avacopan + Avacopan Matching Placebo is a phase 2 stage product being developed by Amgen for C3 Glomerulopathy (C3G). The current trial status is completed. This product is registered under clinical trial identifier NCT03301467. Target conditions include C3 Glomerulopathy (C3G).
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03301467 | Phase 2 | Completed |
Competing Products
5 competing products in C3 Glomerulopathy (C3G)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Iptacopan | Novartis | Pre-clinical | 23 |
| LNP023 | Novartis | Phase 3 | 77 |
| ARO-C3 + Placebo | Arrowhead Pharmaceuticals | Phase 1/2 | 38 |
| BCX9930 | BioCryst Pharmaceuticals | Phase 2 | 47 |
| OMS906 study drug | Omeros Corporation | Phase 2 | 47 |